IDYA analyst estimates
IDEAYA Biosciences (IDYA) analyst ratings, the average price target and its range, and every firm's latest call.
IDYA analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 29, 2026 | Mizuho Securities | Ideaya Biosciences price target lowered to $44 from $50 at Mizuho | $44.00 |
| Sep 9, 2026 | Guggenheim | Ideaya Biosciences price target raised to $57 from $54 at Guggenheim | $57.00 |
| Aug 5, 2026 | Wedbush | Ideaya Biosciences price target raised to $60 from $58 at Wedbush | $60.00 |
| Jul 7, 2026 | RBC Capital | Ideaya Biosciences price target lowered to $48 from $53 at RBC Capital | $48.00 |
| Jul 7, 2026 | Truist Financial | Ideaya Biosciences price target lowered to $63 from $65 at Truist | $63.00 |
| Apr 14, 2026 | RBC Capital | Ideaya Biosciences price target raised to $53 from $49 at RBC Capital | $53.00 |
| Apr 14, 2026 | Wedbush | Ideaya Biosciences price target raised to $58 from $52 at Wedbush | $58.00 |
| Apr 13, 2026 | Truist Financial | Ideaya Biosciences price target raised to $65 from $60 at Truist | $65.00 |
| Feb 18, 2026 | Wedbush | Ideaya Biosciences price target raised to $52 from $49 at Wedbush | $52.00 |
| Jan 21, 2026 | RBC Capital | Ideaya Biosciences price target raised to $45 from $41 at RBC Capital | $45.00 |
| Jan 6, 2026 | Truist Financial | Ideaya Biosciences price target raised to $60 from $59 at Truist | $60.00 |
| Nov 24, 2025 | Truist Financial | Ideaya Biosciences initiated with a Buy at Truist | $59.00 |
| Oct 21, 2025 | RBC Capital | Ideaya Biosciences price target raised to $41 from $38 at RBC Capital | $41.00 |
| Oct 21, 2025 | New Street | Ideaya Biosciences price target raised to $30 from $27 at Goldman Sachs | $30.00 |
| Sep 17, 2025 | Guggenheim | Ideaya Biosciences initiated with a Buy at Guggenheim | $50.00 |
- 11 firms rate IDYA: 10 buy, 1 hold, 0 sell.
- The average price target is $54.40 from 5 analysts, from $44.00 to $63.00.
Updated 2026-11-02 17:51 UTC